Vitiligo
☆ AI Dermatology — Free Service
Natiijooyinka Stiftung Warentest ee 2022 ee ka yimid Jarmalka, ku qanacsanaanta macaamilka ee ModelDerm ayaa waxyar uun ka hooseysay la-talinta telemedicine-ka ee lacagta lagu bixiyo.
Natiijooyinka Stiftung Warentest ee 2022 ee ka yimid Jarmalka, ku qanacsanaanta macaamilka ee ModelDerm ayaa waxyar uun ka hooseysay la-talinta telemedicine-ka ee lacagta lagu bixiyo.
Vitiligo-ga faraha ayaa ka dhib badan in la daweeyo marka loo eego meelaha kale. In kasta oo uu yahay mid aan qurux badneyn, vitiligo waa xaalad caadi ah oo aan la kala qaadi karin. Daaweynta ugu waxtarka badan ee maqaarka waa daaweynta sawir‑qaadista ama daaweynta laser (excimer) oo la sameeyo 2‑3 jeer toddobaadkii, ugu yaraan hal sano. Haddii aadan si joogto ah ugu tegi karin isbitaalka sababo dhaqaale ama jadwal mashquul ah, waxaad isku dayi kartaa mashiinka sawir‑qaadista ee loo oggolaaday in guriga lagu isticmaalo.
Vitiligo isha.
Vitiligo gacanta
relevance score : -100.0%
ReferencesVitiligo waa cillad maqaarka ah oo caadi ah oo keenta maqaarka cad sababtoo ah luminta melanocytes. Cilmi-baaristii ugu dambeysay waxay muujineysaa in uu yahay cudur difaaca jirka. In kasta oo inta badan loo arko arrin la isku qurxiyo, waxay si qoto dheer u saameyn kartaa fayoobida maskaxda iyo nolosha maalinlaha ah. Sannadkii 2011, khubaradu waxay kala saareen nooc loo yaqaan segmental vitiligo, oo ka duwan kuwa kale.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Bukaannada vitiligo ee firfircoon waxay leeyihiin dhowr ikhtiyaar oo daaweyn ah, sida glucocorticoids, daaweynta sawir-qaadista, iyo daaweynta habdhiska difaaca. Bukaannada vitiligo deggan waxay ka heli karaan nasasho corticosteroids-ka la mariyo, calcineurin inhibitors-ka la mariyo maqaarka, daaweynta sawir-qaadista, iyo hababka tallaalka. Horumarkii ugu dambeeyay ee fahamka hababka hoose ee vitiligo ayaa horseeday horumarinta daaweyn la beegsaday. Waqtigan xaadirka ah, JAK inhibitors waa kuwa ugu rajo‑gelinta badan, waxayna bixiyaan dulqaad wanaagsan iyo natiijooyin wax ku ool ah, in kasta oo ay jirto khatar ah in la kiciyo infekshannada qarsoon iyo saameynaha caadiga ah ee wakiilada kale ee difaaca jirka. Cilmi‑baarista socda waxay ujeeddadeedu tahay in la aqoonsado cytokines‑yada muhiimka ah ee ku lug leh horumarinta vitiligo (IFN‑γ, CXCL10, CXCR3, HSP70i, IL‑15, IL‑17/23, TNF). Joojinta cytokines‑kan waxay muujisay ballan‑qaad wanaagsan oo ku saabsan moodooyinka xayawaanka iyo qaar ka mid ah bukaannada. Intaa waxaa dheer, baaritaannada miRNA‑based therapeutics iyo adoptive Treg cell therapy ayaa socda.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Ma jiro daawo la yaqaan oo si gaar ah loogu daweeyo vitiligo. Kuwa maqaarkoodu fudud yahay, kiriimyada qorraxda iyo isqurxinta ayaa ah waxa sida caadiga ah lagula taliyay. Ikhtiyaarada kale ee daawaynta waxaa ka mid noqon kara kiriimyada steroid ama daawaynta sawir‑qaadista.
○ Daawaynta
#Phototherapy
#Excimer laser
#Tacrolimus ointment